Volume 3, Issue 11


Cover Image

Cover Figure: Single-cell tracking map of natural killer cells. Each line represents the trajectory of an individual CD56brightCD16 natural killer cell over 40 minutes. Time-lapse microscopy was performed with an Olympus Xcellence IX81 microscope controlled by Xcellence RT software.
See the article by Stannard et al.

WASHINGTON, D.C., June 11, 2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

The adoptive transfer of cytomegalovirus (CMV)–reactive T cells has been shown to be an effective strategy for the treatment of patients with CMV reactivity and disease refractory to conventional therapies. Khanna et al found that this approach is also effective in the treatment of children with CMV retinitis, further demonstrating the efficacy of this novel approach to the treatment of difficult viral infections.

Patients with high-risk lymphomas have a dismal outcome and novel therapeutic approaches are desperately needed. Genetic and molecular analysis of these diseases have revealed the over expression of c-myc, aurora A kinase, and polo-like kinase-1. Wilcox and colleagues discuss the biological and clinical implications of these findings in an informative review.

In a manuscript from the Children’s Oncology Group, Gaynon and colleagues report outcomes for children with Down syndrome who develop acute lymphocytic leukemia (ALL), showing outstanding long-term results. Their findings highlight the curability of ALL.


Natural killer (NK) cells are attractive for therapeutic purposes due to their ability to recognize and lyse a broad range of tumor cells without prior exposure. However, it is well recognized that NK cells are diverse and express many different cell surface receptors. Stannard and colleague explore further characterization of human NK cells. They identify important subsets, which could inform future clinical translation.

Autologous transplantation for patients with relapsed diffuse large B-cell lymphoma is a standard treatment approach. However, a significant percentage of patients suffer a relapse. Epperla and colleagues detail one of the very largest analyses of the outcomes of patients who relapse following autologous transplantation. This study sets the current standard for the comparison of novel treatments for these patients.

Checkpoint inhibitor therapy has been applied to the treatment of hematological malignancies with mixed results. In an intriguing Commentary, Lesokhin and colleagues discuss the long-term outcomes following treatment of multiple myeloma patients with pembrolizumab, showing ongoing responses in some patients.

Featured Visual Abstract

Neutrophils acquire antigen-presenting cell features after phagocytosis of IgG-opsonized erythrocytes

Sanne M. Meinderts, Gabriella Baker, Stan van Wijk, Boukje M. Beuger, Judy Geissler, Machiel H. Jansen, Anno Saris, Anja ten Brinke, Taco W. Kuijpers, Timo K. van den Berg and Robin van Bruggen


Blood Advances is the open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.